Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department()

AIMS: Ibutilide is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant, approved in the EU in 2010, is likewise used intravenously, with proven efficacy and safety compared with placebo and amiodarone in randomized clinical trials. Th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Europace
Main Authors: Simon, Alexander, Niederdoeckl, Jan, Skyllouriotis, Ekaterini, Schuetz, Nikola, Herkner, Harald, Weiser, Christoph, Laggner, Anton N., Domanovits, Hans, Spiel, Alexander O.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400093/
https://ncbi.nlm.nih.gov/pubmed/28175295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/europace/euw052
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados